Article Versions Notes

Hilhorst R, van den Berg A, Boender P, van Wezel T, Kievits T, de Wijn R, Ruijtenbeek R, Corver WE, Morreau H. Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting. Cancers. 2023; 15(18):4477. https://doi.org/10.3390/cancers15184477

Hilhorst, Riet, Adrienne van den Berg, Piet Boender, Tom van Wezel, Tim Kievits, Rik de Wijn, Rob Ruijtenbeek, Willem E. Corver, and Hans Morreau. 2023. "Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting" Cancers 15, no. 18: 4477. https://doi.org/10.3390/cancers15184477

Hilhorst, R., van den Berg, A., Boender, P., van Wezel, T., Kievits, T., de Wijn, R., Ruijtenbeek, R., Corver, W. E., & Morreau, H. (2023). Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting. Cancers, 15(18), 4477. https://doi.org/10.3390/cancers15184477